Spectrum Pharmaceuticals announced results from the pivotal registrational Phase 2 BELIEF trial of belinostat in treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Belinostat is a pan-histone deacetylase inhibitor.

The BELIEF trial was an open-label, international, single arm efficacy and safety study in patients with relapsed or refractory PTCL who have failed at least one prior systemic therapy. The trial surpassed an objective response rate of at least 20%, the study’s primary efficacy endpoint.

For more information call (949) 788-6700 or visit www.sppirx.com.